Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04968184 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
A Phase 3 study, sponsored by KBP Biosciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 652
- Enrollment target
NCT04968184: Clinical Trial Phase 3 study, sponsored by KBP Biosciences.
NCT04968184 is a Phase 3 study that was terminated before completion, run by KBP Biosciences. The registered enrollment target is 652 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04968184, a Phase 3 study, was terminated before completion, sponsored by KBP Biosciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 652 participants
- Enrollment target
Study Summary
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate \[eGFR\] calculated using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula \[eGFR {EPI}\] ≥15 to ≤44 mL/min/1.73 m\^2) and uncontrolled hypertension (systolic blood pressure (SBP) ≥140 and \<180 mm Hg and taking 2 or more antihypertensive medications.
Primary Outcome
Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, will be evaluated.
Interventions
- DRUG Placebo
- DRUG KBP-5074
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 652 participants |
| Start Date | 2021-11-05 |
| Est. Completion | 2024-07-10 |
| Phase | Phase 3 |
Why NCT04968184 stopped before completion
NCT04968184 is an interventional study that assigns participants to a tested intervention. The registered 652 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04968184 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04968184 about?
NCT04968184 is a clinical study titled "Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)". This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate ...
What is the current status of trial NCT04968184?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 652 participants. The study started on 2021-11-05. Estimated completion is 2024-07-10.
What interventions are being tested in trial NCT04968184?
The interventions under investigation include: Placebo (DRUG), KBP-5074 (DRUG).
Who is sponsoring clinical trial NCT04968184?
This trial is sponsored by KBP Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04968184's enrollment target sits among peer trials
652 571st of 2000 higher than 1,429 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06287346 · 652 participants
5-Years PMCF Study of Ceramic Dental Implants One-piece Versus Two-piece.
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI